Lung adenocarcinoma RET gene mutation-targeted drugs refer to the inhibitors for lung adenocarcinoma with RET mutation gene, which mainly include: vandetanib, cabozantinib and so on. 1. Vandetanib is a multi-target tyrosine kinase inhibitor, inhibiting the transmission of vascular endothelial growth factor receptor 2, EGFR and RET signaling pathway. It has been reported that patients with RET mutation-positive lung adenocarcinoma who have been treated with vandetanib for 4 months have their lesions shrunk by 76%, which suggests that patients with RET mutation-positive lung adenocarcinomas are sensitive to vandetanib. 2. Cabozantinib: It is a multi-receptor tyrosine kinase inhibitor with activity against RET, and produces anti-tumor effect by blocking MET proto-oncogene receptor tyrosine kinase, vascular endothelial growth factor receptor 2 and RET signaling pathway. If you are suffering from lung adenocarcinoma, you should actively receive treatment.